Observational studyBMC pregnancy and childbirth2026
Iron supplementation-induced modulation of hepcidin, erythroferrone, and oxidative balance in iron-deficient pregnant women.
Observational study in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIron deficiency anemia affects approximately 40% of pregnant women worldwide, associated with increased oxidative stress (OS) and adverse pregnancy outcomes. Recent advances identified hepcidin as the master regulator of iron homeostasis and erythroferrone (ERFE) as a key erythroid regulator, yet their responses to iron supplementation and relationships with OS markers during pregnancy remain poorly understood.
objectiveTo investigate whether oral iron supplementation reduces OS in pregnant women with IDA and characterize relationships between iron regulatory molecules (hepcidin, ERFE) and OS biomarkers.
methodsThis single-arm observational study without placebo controls enrolled 40 pregnant women with IDA (mean age 29.23 ± 6.33 years) across all trimesters. Participants received 200 mg elemental iron daily for one month. Pre- and post-treatment measurements included hematologic parameters, iron metabolism markers (ferritin, hepcidin, ERFE), and OS biomarkers (total antioxidant status [TAS], total oxidant status [TOS]).
resultsIron supplementation was associated with significant improvements in TAS (0.96 ± 0.36 to 1.64 ± 0.37mmol Trolox Equiv./L; Cohen’s d = 1.87, p < 0.001), exceeding hematological improvements in hemoglobin (10.10 ± 0.72 to 11.61 ± 0.97 g/dL; d = 1.76, p < 0.001) and hematocrit (30.93 ± 1.79% to 35.24 ± 3.01%; d = 1.74, p < 0.001). The TOS/TAS ratio decreased significantly (14.53 ± 15.98 to 4.10 ± 3.14 U/mmol Trolox Equiv.; d = -0.91, p < 0.001). Hepcidin increased (2214.62 ± 1444.27 to 3492.65 ± 1640.51 pg/mL; d = 0.83, p < 0.001) while ERFE decreased (470.75 ± 170.75 to 345.25 ± 112.96 pg/mL; d = -0.87, p < 0.001), consistent with successful iron repletion. Notably, significant Trimester × Time interactions were observed for both hormones (hepcidin: ηp2 = .452; ERFE: ηp2 = .462, both p < 0.001), with hepcidin elevation progressively increasing across trimesters and ERFE suppression maximal during second trimester. TAS improvements showed minimal correlation with iron parameters (all |r|< 0.25), suggesting potentially independent mechanisms.
conclusionsIron supplementation was associated with reduced OS in pregnant women with IDA through mechanisms potentially independent of iron parameter changes. The coordinated hormonal responses are consistent with appropriate iron repletion while suggesting additional therapeutic benefits beyond anemia correction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.